Key Details
Annual ROE
-211.20%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Aug 10, 2022Recent annual earnings:
Mar 31, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
07 Dec '23 Maxim Group
BuyScreeners with DMK included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
DMK Pharmaceuticals doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of DMK Pharmaceuticals?
- What is the ticker symbol for DMK Pharmaceuticals?
- Does DMK Pharmaceuticals pay dividends?
- What sector is DMK Pharmaceuticals in?
- What industry is DMK Pharmaceuticals in?
- What country is DMK Pharmaceuticals based in?
- Is DMK Pharmaceuticals in the S&P 500?
- Is DMK Pharmaceuticals in the NASDAQ 100?
- Is DMK Pharmaceuticals in the Dow Jones?
- When was DMK Pharmaceuticals's last earnings report?
- When does DMK Pharmaceuticals report earnings?
- Should I buy DMK Pharmaceuticals stock now?
What is the primary business of DMK Pharmaceuticals?
DMK Pharmaceuticals Corporation, a clinical stage neuro-biotechnology company, develops and commercializes products in the therapeutic areas of allergy, opioid overdose, respiratory, and inflammatory diseases. The company's lead clinical stage product candidate, DPI-125, which is indicated for the treatment of opioid use disorder. Its products include SYMJEPI epinephrine injection for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens, as well as idiopathic or exercise-induced anaphylaxis; and ZIMHI naloxone injection for the treatment of opioid overdose. The company was formerly known as Adamis Pharmaceuticals Corporation and changed its name to DMK Pharmaceuticals Corporation in September 2023. The company is headquartered in San Diego, California. On February 2, 2024, DMK Pharmaceuticals Corporation, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
What is the ticker symbol for DMK Pharmaceuticals?
The ticker symbol for DMK Pharmaceuticals is NASDAQ:DMK
Does DMK Pharmaceuticals pay dividends?
No, DMK Pharmaceuticals does not pay dividends
What sector is DMK Pharmaceuticals in?
DMK Pharmaceuticals is in the Healthcare sector
What industry is DMK Pharmaceuticals in?
DMK Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry
What country is DMK Pharmaceuticals based in?
DMK Pharmaceuticals is headquartered in United States
Is DMK Pharmaceuticals in the S&P 500?
No, DMK Pharmaceuticals is not included in the S&P 500 index
Is DMK Pharmaceuticals in the NASDAQ 100?
No, DMK Pharmaceuticals is not included in the NASDAQ 100 index
Is DMK Pharmaceuticals in the Dow Jones?
No, DMK Pharmaceuticals is not included in the Dow Jones index
When was DMK Pharmaceuticals's last earnings report?
DMK Pharmaceuticals's most recent earnings report was on 10 August 2022
When does DMK Pharmaceuticals report earnings?
The date for DMK Pharmaceuticals's next earnings report has not been announced yet
Should I buy DMK Pharmaceuticals stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions